Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 6/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | FBP1 | P09467 | 1/20 | 0.39 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21536746 | 0.84 | DUT (0.49) | DUTALDH1A1TSHRFBP1MEP1B | |
| SCHEMBL20189787 | 0.83 | DUT (0.61) | DUTALDH1A1TSHRFBP1MTNR1A | |
| SCHEMBL20189790 | 0.81 | DUT (0.61) | DUTALDH1A1TSHRFBP1 | |
| SCHEMBL21536107 | 0.81 | DUT (0.46) | DUTALDH1A1MTNR1AMAPK1 | |
| SCHEMBL21522296 | 0.81 | DUT (0.58) | DUTALDH1A1TSHRMAPK1NPSR1 | |
| SCHEMBL20190941 | 0.80 | DUT (0.58) | DUTALDH1A1TSHRFBP1 | |
| SCHEMBL1409637 | 0.79 | DUT (0.65) | DUTALDH1A1TSHRMAPK1NPSR1 | |
| SCHEMBL20189610 | 0.78 | DUT (0.58) | DUTALDH1A1TSHRFBP1MAPK1 | |
| SCHEMBL20189771 | 0.78 | DUT (0.49) | DUTALDH1A1FBP1MTNR1AMAPK1 | |
| SCHEMBL21690361 | 0.77 | DUT (0.64) | DUTALDH1A1TSHRMTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11168059-B2 | Amino sulfonyl compounds | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2021-11-09 | — | — | US | disclosed |
| US-20190330158-A1 | AMINO SULFONYL COMPOUNDS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2019-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11168059-B2 | Amino sulfonyl compounds | DPYD, DNPEP, DUT | DUT 3/4885ALDH1A1 2924/4885TSHR 4510/4885 |
| US-20190330158-A1 | AMINO SULFONYL COMPOUNDS | DPYD, DNPEP, DUT | DUT 3/4885ALDH1A1 2924/4885TSHR 4510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.